NASDAQ:MGX | Free Cash Flow | Metagenomi Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2023-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$21.18M$25,000.00-$21.2M
2025-12-31-$23.55M$85,000.00-$23.63M
2025-03-31-$22.84M$288,000.00-$23.13M
2024-12-31-$26.28M$334,000.00-$26.61M
2024-03-31-$29.85M$915,000.00-$30.77M
2023-12-31-$20.59M$1.74M-$22.33M
2023-03-31-$21M$2.67M-$23.66M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$88.89M$574,000.00-$89.47M
2024-12-31-$109.07M$3.11M-$112.19M
2023-12-31-$91.41M$9.81M-$101.22M